Retatrutide is the third step in a sequence. Semaglutide activates one incretin receptor, tirzepatide activates two, and retatrutide activates three. For the background on that single, dual, and triple framing, the complete GLP-1 research guide is the place to start; this piece focuses on retatrutide specifically and on the trial programme testing it.
The important word throughout is investigational. As of 2026 retatrutide is not an approved medicine. Every figure below is a clinical-trial result, reported under a trial’s specific conditions, not a claim about an approved product. That distinction matters more here than for the older compounds, because there is no approved label to fall back on.
The third receptor
Retatrutide is a single engineered peptide that activates the GLP-1, GIP, and glucagon receptors together. The first two are the incretin receptors that the earlier GLP-1 compounds already engage. The new one is glucagon.
Glucagon is usually discussed as the hormone that raises blood sugar, which sounds like the opposite of what a metabolic compound would want. The research rationale is different: at the receptor level, glucagon-receptor agonism is associated with increased energy expenditure and with fat metabolism in the liver. The design idea is that GLP-1 and GIP handle appetite and insulin response, while the glucagon component adds an energy-expenditure and hepatic-fat angle the incretins alone do not cover. Whether that translates into a larger and tolerable effect in people is precisely the question the trials exist to answer, and it is not settled.
That liver angle is being studied directly. A separate Phase 2a trial in metabolic-dysfunction-associated steatotic liver disease looked at retatrutide’s effect on liver fat, which is the kind of endpoint the glucagon component is specifically expected to move.
What the Phase 2 trial reported
Retatrutide’s first major human evidence came from a Phase 2 trial published in 2023, registered as NCT04881760. It randomised 338 adults with obesity, or with overweight plus a weight-related condition, to weekly retatrutide at 1, 4, 8, or 12 mg, or to placebo, over 48 weeks.
The result that drew attention was the size of the effect and how cleanly it tracked with dose:
At the top 12 mg dose the average reduction was about 24% at 48 weeks, against roughly 2% on placebo. The trial had earlier met its primary endpoint at 24 weeks, with an average reduction of up to 17.5% reported at that mid-point. Two things are worth holding onto. First, these are averages: individual results in any trial span a wide range around the mean. Second, this is a single Phase 2 trial, which is why the dose comparison above is fair to read directly, and also why it was only ever a signal that a larger programme had to confirm.
The most common adverse effects were gastrointestinal, nausea, vomiting, and diarrhoea, which is the pattern seen across this whole class rather than anything specific to retatrutide.
The TRIUMPH programme
That larger programme is TRIUMPH, the Phase 3 stage, launched in 2023. It is substantially bigger than the Phase 2 work: more than 5,800 participants across a set of trials that reach well beyond a single weight-loss question. The programme spans obesity on its own, obesity with type 2 diabetes, obesity with established cardiovascular disease, knee osteoarthritis, and obstructive sleep apnea, among other conditions.
The reason for that breadth is that the Phase 2 signal touched several systems at once, weight, blood sugar, liver fat, so Phase 3 is testing the compound against several distinct endpoints rather than one. TRIUMPH is not a single trial; it is a family of them under one banner, each with its own population and primary outcome.
Early Phase 3 readouts have continued the pattern from Phase 2. The first TRIUMPH results reported average reductions in the region of 28%, with a large proportion of participants reaching a 30% reduction at the higher doses over the longer treatment period. As with everything here, those are trial figures for an investigational compound, reported under the trial’s conditions.
How to read this, honestly
Retatrutide has produced the largest average reductions reported in this class so far. It is also the least far along: still in Phase 3, not approved, and without the multi-year post-approval record that semaglutide and tirzepatide have accumulated. Size of reported effect and depth of evidence are separate things, and on the second measure retatrutide is the newcomer. The three-way comparison of semaglutide, tirzepatide, and retatrutide sets those trade-offs side by side.
A few cautions specific to reading a programme like TRIUMPH:
- Averages are not individuals. A headline “28%” is a group mean. The spread around it is wide, and the trial reports that spread for anyone who reads past the summary.
- Cross-trial numbers are not a ranking. A retatrutide figure from one trial and a tirzepatide figure from another were measured in different populations over different durations. They are directional, not a scoreboard.
- Investigational means unfinished. Phase 3 exists to test safety and durability at scale, not just to confirm a weight number. Until it reports in full and regulators review it, the picture is genuinely incomplete.
For the wider framing of how these compounds relate, and how to read a GLP-1 trial without over-reading it, start with the complete GLP-1 research guide.